Trial Profile
A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms BEECH
- Sponsors AstraZeneca
- 05 Oct 2022 Status changed from active, no longer recruiting to completed.
- 24 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.
- 16 Dec 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.